Literature DB >> 11812090

Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha(v)-integrin.

Yael S Schiffenbauer1, Gila Meir, Miriam Maoz, Sharona Cohen Even-Ram, Rachel Bar-Shavit, Michal Neeman.   

Abstract

OBJECTIVE: The goal of this work was to evaluate the involvement of gonadotropins in the regulation of adhesion of human epithelial ovarian carcinoma. We studied two pathways that were previously implicated in the metastatic implantation of ovarian carcinoma to the peritoneum, namely hyaluronan-CD44 and RGD-integrin mediated adhesion.
METHODS: Two cell lines derived from human epithelial ovarian carcinoma (MLS and OC238) were stimulated with luteinizing hormone (LH) and/or follicle stimulating hormone (FSH). Expression of CD44 was evaluated by Western blotting. Expression of alpha(v)-integrins was studied by RT-PCR and Northern blot. Integrin and CD44 mediated adhesion of the cells was analyzed using culture plates coated either with a thrombin derived RGD containing peptide or fibronectin for integrin mediated adhesion or with hyaluronan for CD44 mediated adhesion.
RESULTS: MLS cells stimulated with either LH or FSH showed increased adhesion to culture plates coated with hyaluronan, as well as to culture plates coated with fibronectin or with a thrombin derived RGD containing peptide. In these cells, gonadotropin stimulation led to induced expression of the integrin subunit alpha(v) and CD44, the cell surface hyaluronan receptor. On the other hand, OC238 cells showed no expression of the integrin subunit alpha(v) and no hormonal effect on the expression of CD44. Accordingly, adhesion of OC238 cells on either RGD or CD44 was not affected by hormonal stimulation.
CONCLUSION: Elevated levels of gonadotropins may in some cases facilitate peritoneal metastatic dissemination of ovarian cancer by increasing cell adhesion, the first essential step in the invasion process. ©2002 Elsevier Science.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812090     DOI: 10.1006/gyno.2001.6512

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Kinetic analysis of hyaluronidase activity using a bioactive MRI contrast agent.

Authors:  Liora Shiftan; Michal Neeman
Journal:  Contrast Media Mol Imaging       Date:  2006 May-Jun       Impact factor: 3.161

Review 2.  Microenvironment and pathogenesis of epithelial ovarian cancer.

Authors:  Antonio F Saad; Wei Hu; Anil K Sood
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

3.  Gonadotropin-regulated lymphangiogenesis in ovarian cancer is mediated by LEDGF-induced expression of VEGF-C.

Authors:  Stav Sapoznik; Batya Cohen; Yael Tzuman; Gila Meir; Shifra Ben-Dor; Alon Harmelin; Michal Neeman
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

4.  Role of VEGF and CD44v6 in differentiating benign from malignant ascites.

Authors:  Wei-Guo Dong; Xiao-Min Sun; Bao-Ping Yu; He-Sheng Luo; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

5.  Harnessing competing endocytic pathways for overcoming the tumor-blood barrier: magnetic resonance imaging and near-infrared imaging of bifunctional contrast media.

Authors:  Helena Sheikhet Migalovich; Vyacheslav Kalchenko; Nava Nevo; Gila Meir; Fortune Kohen; Michal Neeman
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

6.  Peritoneal adhesion and angiogenesis in ovarian carcinoma are inversely regulated by hyaluronan: the role of gonadotropins.

Authors:  Yael Chagit Tzuman; Stav Sapoznik; Dorit Granot; Nava Nevo; Michal Neeman
Journal:  Neoplasia       Date:  2010-01       Impact factor: 5.715

7.  In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors.

Authors:  Dorit Granot; Yoseph Addadi; Vyacheslav Kalchenko; Alon Harmelin; Leoni A Kunz-Schughart; Michal Neeman
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

8.  Expression of the luteinizing hormone receptor (LHR) in ovarian cancer.

Authors:  Shigang Xiong; Paulette Mhawech-Fauceglia; Denice Tsao-Wei; Lynda Roman; Rajesh K Gaur; Alan L Epstein; Jacek Pinski
Journal:  BMC Cancer       Date:  2019-11-15       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.